This is the first study to demonstrate the existence of a clinically significant subgroup of patients with HER-2-positive early breast cancer, who experience a favourable long-term outcome that can be identified with a validated and commercially available gene expression assay. The gene discussed is ERBB2; the disease is breast carcinoma.